• Global biomedical investment showed signs of recovery in 2026, but funding concentrated in fewer companies without a corresponding rise in deal counts.
• AI is becoming standard across digital health, shifting competitive advantage toward clinical workflow integration and solutions addressing unmet care needs.
• Commercial viability depends on reimbursement, willingness to pay and addressable markets; technical innovation alone does not ensure sustainable revenue.
• Cash flow, fundraising capacity and credible exits remain decisive investment criteria, with acquisitions particularly relevant for biotech and medical device startups.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sustainable Impact Capital Co Ltd published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.